FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000984979> ?p ?o ?g. }

• W2000984979 endingPage "996" @default.
• W2000984979 startingPage "993" @default.
• W2000984979 abstract "Docetaxel has shown promise for the treatment of hormone-refractory prostate cancer and has become the standard of care. The flare phenomenon is a known entity in androgen-deprivation therapy of advanced prostate cancer and it has also been described in palliative chemotherapy of hormone-refractory prostate cancer. The aim of this study was to evaluate the clinical impact of a prostate-specific antigen flare phenomenon in docetaxel-treated hormone-refractory prostate cancer patients. From December 2002 to August 2005, we treated 44 patients with hormone-refractory prostate cancer applying docetaxel-based regimens. Prostate-specific antigen levels were determined before therapy and weekly thereafter. Patients were divided into three groups: response (group 1), progression (group 2) and flare (group 3). Flare was defined as initially rising prostate-specific antigen under therapy, dropping thereafter to values below baseline. The groups were compared for overall survival by Kaplan-Meier analysis. We observed a prostate-specific antigen flare phenomenon in eight (18%) of 44 evaluable patients; 24 (54.5%) patients were primary responders and 12 (27.3%) experienced progressive disease. In group 3, prostate-specific antigen levels rose to 107-180% from baseline and then dropped to 21-68%. Kaplan-Meier analysis showed significantly better overall median survival for groups 1 (18 months, P=0.0005) and 3 (19 months, P=0.006) than for group 2 (7 months). Survival in groups 1 and 3 was comparable. Grade 3 and 4 toxicity was below 5% and equally distributed between the 3 groups. In our limited patient cohort, prostate-specific antigen flare phenomenon does not seem to be a clinically relevant issue in terms of overall survival. Thus, an initial rise of prostate-specific antigen under docetaxel therapy in hormone-refractory prostate cancer does not indicate therapeutic failure and should not lead to early withdrawal from therapy in the absence of clinical signs of progression." @default.
• W2000984979 created "2016-06-24" @default.
• W2000984979 creator A5001792237 @default.
• W2000984979 creator A5041753370 @default.
• W2000984979 creator A5048118430 @default.
• W2000984979 creator A5060689253 @default.
• W2000984979 creator A5060890272 @default.
• W2000984979 creator A5073359794 @default.
• W2000984979 date "2006-09-01" @default.
• W2000984979 modified "2023-10-18" @default.
• W2000984979 title "Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel" @default.
• W2000984979 cites W1854708637 @default.
• W2000984979 cites W1893347245 @default.
• W2000984979 cites W1907260682 @default.
• W2000984979 cites W1964413003 @default.
• W2000984979 cites W2008408544 @default.
• W2000984979 cites W2015024838 @default.
• W2000984979 cites W2022008209 @default.
• W2000984979 cites W2023275561 @default.
• W2000984979 cites W2043478531 @default.
• W2000984979 cites W2058917998 @default.
• W2000984979 cites W2063113306 @default.
• W2000984979 cites W2069109889 @default.
• W2000984979 cites W2080439368 @default.
• W2000984979 cites W2103604721 @default.
• W2000984979 cites W2120292596 @default.
• W2000984979 cites W2128686715 @default.
• W2000984979 cites W4296140011 @default.
• W2000984979 doi "https://doi.org/10.1097/01.cad.0000231468.69535.97" @default.
• W2000984979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16940810" @default.
• W2000984979 hasPublicationYear "2006" @default.
• W2000984979 type Work @default.
• W2000984979 sameAs 2000984979 @default.
• W2000984979 citedByCount "36" @default.
• W2000984979 countsByYear W20009849792013 @default.
• W2000984979 countsByYear W20009849792014 @default.
• W2000984979 countsByYear W20009849792015 @default.
• W2000984979 countsByYear W20009849792016 @default.
• W2000984979 countsByYear W20009849792017 @default.
• W2000984979 countsByYear W20009849792018 @default.
• W2000984979 countsByYear W20009849792019 @default.
• W2000984979 countsByYear W20009849792020 @default.
• W2000984979 countsByYear W20009849792022 @default.
• W2000984979 crossrefType "journal-article" @default.
• W2000984979 hasAuthorship W2000984979A5001792237 @default.
• W2000984979 hasAuthorship W2000984979A5041753370 @default.
• W2000984979 hasAuthorship W2000984979A5048118430 @default.
• W2000984979 hasAuthorship W2000984979A5060689253 @default.
• W2000984979 hasAuthorship W2000984979A5060890272 @default.
• W2000984979 hasAuthorship W2000984979A5073359794 @default.
• W2000984979 hasConcept C121608353 @default.
• W2000984979 hasConcept C126322002 @default.
• W2000984979 hasConcept C126894567 @default.
• W2000984979 hasConcept C143998085 @default.
• W2000984979 hasConcept C2776235491 @default.
• W2000984979 hasConcept C2777899217 @default.
• W2000984979 hasConcept C2780192828 @default.
• W2000984979 hasConcept C2781190966 @default.
• W2000984979 hasConcept C2781406297 @default.
• W2000984979 hasConcept C71924100 @default.
• W2000984979 hasConceptScore W2000984979C121608353 @default.
• W2000984979 hasConceptScore W2000984979C126322002 @default.
• W2000984979 hasConceptScore W2000984979C126894567 @default.
• W2000984979 hasConceptScore W2000984979C143998085 @default.
• W2000984979 hasConceptScore W2000984979C2776235491 @default.
• W2000984979 hasConceptScore W2000984979C2777899217 @default.
• W2000984979 hasConceptScore W2000984979C2780192828 @default.
• W2000984979 hasConceptScore W2000984979C2781190966 @default.
• W2000984979 hasConceptScore W2000984979C2781406297 @default.
• W2000984979 hasConceptScore W2000984979C71924100 @default.
• W2000984979 hasIssue "8" @default.
• W2000984979 hasLocation W20009849791 @default.
• W2000984979 hasLocation W20009849792 @default.
• W2000984979 hasOpenAccess W2000984979 @default.
• W2000984979 hasPrimaryLocation W20009849791 @default.
• W2000984979 hasRelatedWork W1992657261 @default.
• W2000984979 hasRelatedWork W2038565121 @default.
• W2000984979 hasRelatedWork W2060708716 @default.
• W2000984979 hasRelatedWork W2127440557 @default.
• W2000984979 hasRelatedWork W2148869351 @default.
• W2000984979 hasRelatedWork W2588988563 @default.
• W2000984979 hasRelatedWork W2770702948 @default.
• W2000984979 hasRelatedWork W2897445903 @default.
• W2000984979 hasRelatedWork W3129209394 @default.
• W2000984979 hasRelatedWork W4281788288 @default.
• W2000984979 hasVolume "17" @default.
• W2000984979 isParatext "false" @default.
• W2000984979 isRetracted "false" @default.
• W2000984979 magId "2000984979" @default.
• W2000984979 workType "article" @default.